4-propyl-heptanoic acid | 6796-27-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-propyl-heptanoic acid
• 英文别名: 3-Propyl-hexan-carbonsaeure-(1)；4-Propyl-oenanthsaeure；4-Propyl-heptansaeure；4-n-propyl-heptanoic acid；4-n-Propyl-heptancarbonsaeure；4-Propylheptanoic acid
• CAS: 6796-27-6
• 化学式: C₁₀H₂₀O₂
• 分子量: 172.268
• InChiKey: KEVIAJOKJAAXQZ-UHFFFAOYSA-N

物化性质

• 沸点：
  146-147 °C(Press: 13 Torr)
• 密度：
  0.913±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  4-propyl-heptanoic acid 在 三氯化铝 、 氯化亚砜 作用下， 生成 γ-Propyl-oenanthophenon
  参考文献：
  名称：

  Studt,P., Justus Liebigs Annalen der Chemie, 1966, vol. 693, p. 90 - 98

  摘要：

  DOI：
• 作为产物：
  描述：

  4-propyl-heptanenitrile 生成 4-propyl-heptanoic acid
  参考文献：
  名称：

  Keil, Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1947, vol. 282, p. 139

  摘要：

  DOI：

文献信息

• Acetic acid derivatives having pharmacological activity and compositions
  申请人：Labaz

  公开号：US04025649A1

  公开（公告）日：1977-05-24

  Acetic acid derivatives of the formula: ##STR1## and pharmaceutically acceptable alkali metal salts thereof, wherein R represents the radical ##STR2## in which R.sub.1 and R.sub.2, which may be the same or different, each represent an alkyl radical having from 1 to 4 carbon atoms, R.sub.3 represents a hydrogen atom or a methyl radical and n is an integer in the range of from 0 to 3 inclusive. They possess a competitive inhibitory activity with respect to .gamma.-aminobutyric .alpha.-ketoglutaric transaminase as well as antianoxic and anticonvulsant properties and they are useful for treating central neurological disorders whether resulting or not from cerebral ischemia.

  乙酸衍生物的化学式为：##STR1##及其在药学上可接受的碱金属盐，其中R代表基团##STR2##其中R.sub.1和R.sub.2，可以相同也可以不同，每个代表具有1至4个碳原子的烷基基团，R.sub.3代表氢原子或甲基基团，n是在0至3范围内的整数。它们具有相对于γ-氨基丁酸α-酮戊二酸转氨酶的竞争性抑制活性，以及抗缺氧和抗抽搐特性，可用于治疗中枢神经系统疾病，无论是由脑缺血引起还是其他原因。
• INSOLUBLE INSULIN COMPOSITIONS
  申请人：ELI LILLY AND COMPANY

  公开号：EP0911035A2

  公开（公告）日：1999-04-28

  The present invention relates to insoluble compositions containing acylated proteins selected from the group consisting of acylated insulin, acylated insulin analog, and acylated proinsulin, and formulations thereof. The formulations are suitable for parenteral delivery or other means of delivery, to a patient for extended control of blood glucose levels. More particularly, the present invention relates to compositions comprised of an acylated protein complexed with zinc, protamine, and a phenolic compound such that the resulting microcrystal is analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that compositions of such acylated proteins have therapeutically superior subcutaneous release pharmacokinetics, and more extended and flatter glucodynamics, than presently available commercial preparations of NPH insulin. Yet, the present crystals retain certain advantageous properties of NPH crystals, being readily able to be resuspended and also mixable with soluble insulins.

  本发明涉及含有选自由酰化胰岛素、酰化胰岛素类似物和酰化原胰岛素组成的组中的酰化蛋白质的不溶性组合物及其制剂。这些制剂适用于肠道外给药或以其他方式给药，以延长对患者血糖水平的控制。更具体地说，本发明涉及一种由酰化蛋白质与锌、原胺和酚类化合物络合而成的组合物，由此产生的微晶类似于中性原胺哈格多恩（NPH）胰岛素晶型。令人惊奇的是，人们发现这种酰化蛋白质的组合物与目前市售的 NPH 胰岛素商业制剂相比，具有更优越的皮下释放药代动力学和更持久、更平稳的血糖动力学。然而，目前的晶体仍保留了 NPH 晶体的某些有利特性，易于重新悬浮，也可与可溶性胰岛素混合。
• Insoluble compositions for controlling blood glucose
  申请人：ELI LILLY AND COMPANY

  公开号：EP0925792A2

  公开（公告）日：1999-06-30

  The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.

  本发明涉及不溶性组合物，该组合物包含选自由胰岛素、胰岛素类似物和原胰岛素组成的组的蛋白质；选自由衍生化胰岛素、衍生化胰岛素类似物和衍生化原胰岛素组成的组的衍生化蛋白质；复合物；六聚体稳定化合物；以及二价金属阳离子。不溶性组合物的制剂既适用于肠道外给药，也适用于治疗高血糖和糖尿病的非肠道外给药。不溶性沉淀物的微晶形式在药学上类似于中性原明哈格登（NPH）胰岛素晶体形式。令人惊奇的是，人们发现这种不溶性组合物的悬浮制剂具有独特的可控溶解特性，与 NPH 胰岛素制剂相比，这种悬浮制剂具有治疗上有利的血糖动力学特性。
• Insoluble Insulin Compositions for Controlling Blood Glucose
  申请人：Eli Lilly & Company

  公开号：EP1396272A1

  公开（公告）日：2004-03-10

  The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.

  本发明涉及不溶性组合物，该组合物包含选自由胰岛素、胰岛素类似物和原胰岛素组成的组的蛋白质；选自由衍生化胰岛素、衍生化胰岛素类似物和衍生化原胰岛素组成的组的衍生化蛋白质；复合物；六聚体稳定化合物；以及二价金属阳离子。不溶性组合物的制剂既适用于肠道外给药，也适用于治疗高血糖和糖尿病的非肠道外给药。不溶性沉淀物的微晶形式在药学上类似于中性原明哈格登（NPH）胰岛素晶体形式。令人惊奇的是，人们发现这种不溶性组合物的悬浮制剂具有独特的可控溶解特性，与 NPH 胰岛素制剂相比，这种悬浮制剂具有治疗上有利的血糖动力学特性。
• Insoluble insulin compositions
  申请人：——

  公开号：US20010036916A1

  公开（公告）日：2001-11-01

  The present invention relates to insoluble compositions containing acylated proteins selected from the group consisting of acylated insulin, acylated insulin analog, and acylated proinsulin, and formulations thereof. The formulations are suitable for parenteral delivery or other means of delivery, to a patient for extended control of blood glucose levels. More particularly, the present invention relates to compositions comprised of an acylated protein complexed with zinc, protamine, and a phenolic compound such that the resulting microcrystal is analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that compositions of such acylated proteins have therapeutically superior subcutaneous release pharmacokinetics, and more extended and flatter glucodynamics, than presently available commercial preparations of NPH insulin. Yet, the present crystals retain certain advantageous properties of NPH crystals, being readily able to be resuspended and also mixable with soluble insulins.

  本发明涉及含有选自由酰化胰岛素、酰化胰岛素类似物和酰化原胰岛素组成的组中的酰化蛋白质的不溶性组合物及其制剂。这些制剂适用于肠道外给药或以其他方式给药，以延长对患者血糖水平的控制。更具体地说，本发明涉及一种由酰化蛋白质与锌、原胺和酚类化合物络合而成的组合物，由此产生的微晶类似于中性原胺哈格多恩（NPH）胰岛素晶型。令人惊奇的是，人们发现这种酰化蛋白质的组合物与目前市售的 NPH 胰岛素商业制剂相比，具有更优越的皮下释放药代动力学和更持久、更平稳的血糖动力学。然而，目前的晶体仍保留了 NPH 晶体的某些有利特性，易于重新悬浮，也可与可溶性胰岛素混合。